[Atypical organ-oriented effects of so-called ovulation inhibitors following bilateral nephrectomy, as well as unusual endometrial changes during long-term acyclinc therapy for chronicmyelosis].
D000307:Adrenal Gland Diseases / Q000139:chemically induced; D000328:Adult; D001940:Breast / Q000473:pathology; D056486:Chemical and Drug Induced Liver Injury; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000601:surgery; D008099:Liver / Q000473:pathology; D008234:Lynestrenol / Q000009:adverse effects*; D008595:Menorrhagia / Q000188:drug therapy; D008656:Mestranol / Q000009:adverse effects*; D008796:Metrorrhagia / Q000188:drug therapy; D009336:Necrosis; D009392:Nephrectomy; D011247:Pregnancy; D055728:Primary Myelofibrosis / Q000150:complications; D011555:Pseudopregnancy; D011704:Pyelonephritis / Q000150:complications; D013997:Time Factors; D014511:Uremia / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000139:chemically induced; D014599:Uterus / Q000473:pathology
D003276:Contraceptives, Oral; D008656:Mestranol; D008234:Lynestrenol
Atypische Oranwirkungen sogenannter Ovulationshemer nach bilateraler Nephrektomie, sowie ungerwöhnliche Endometriumveränderungen während azyklischer Dauertherapie wegen chronischer Myelose.